)
)
)
OS Therapies
OS Therapies is a publicly traded (OSTX) clinical-stage biotech company focused on new therapeutics for osteosarcoma and other solid tumors. We have two platform technologies: 1) OST-HER2 is an off-the-shelf immunotherapy currently under regulatory review to be the first treatment ever in metastatic osteosarcoma, add first new therapy in osteosarcoma in over 40 years.
Our other platform technology: 2) OST-tADC is a tunable ADC delivery system with ph-sensitive linkers and conditionally active, multiple payloads.
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
